Why CEU's

Detail your services 

 Continuing Education Units (CEUs) are intended to broaden the knowledge base of the professional technologist. The CSCT and OSCT’s goal is to maintain a high standard of excellence and quality within our membership. The following CEU guidelines will help guide members in their endeavor to obtain CEUs. CEUs should be obtained from current sources and add to the basic knowledge members received during their schooling and subsequent employment, therefore CEUs must be above entry level to practice or “basic level” to earn units. Subject matter that a member is reasonably expected to have learned prior to writing the CSCT exam cannot be accepted as a continuing education unit i.e. Cardiac physiology, normal heart rhythms, etc. Below are some guidelines to support members in their endeavor to obtain CEUs. Advanced CEUs are routinely provided through both the OSCT and CSCT websites. 

CEU Standards Guidelines

1. Only CEUs accumulated and submitted during the current triennium will be accepted.

2. Documentation or proof of attendance must accompany all CEU submissions. Members are responsible for keeping originals of all documentation in case of a discrepancy. CEU coordinators may or may not keep copies of CEU’s obtained.

3. Every submission must be Cardiology related.

4. Job requirements may not necessarily meet the criteria for CEU’s. i.e. code blue review, hardware/software instructions

5. Formal classes must be from an accredited program and must fall under the NOCP guidelines.

6. Preceptors must be for a Cardiology Technology program or CLXT/MLA and from an accredited program recognized by the CSCT

7. Members will receive 1 CEU for every 30-minute video cited, or 2 CEU’s if there is a summary written about it.

8. Members must submit the learning objective and instructor for any lectures or in-services. If it falls under “entry level to practice” according to the NOCP guidelines, members will only receive 2 CEU’s per triennium for these activities.

9. CEU’s for teaching will not be granted if you are being paid as an instructor from an educational institution. They must be accumulated for teaching during working hours or volunteering after hours.  

Duration: 1 hour

CEU Value: 1

CSCT CEU STANDARDS SECTION: 2F

Link:     TAVR in Patients with Bicuspid Anatomy | myCME   

Expires: November 16, 2022

Description:

Program Description

Although patients with a bicuspid aortic valve (BAV) currently account for nearly half of aortic valve replacement (AVR) procedures, they were excluded from the pivotal clinical trials leading to US Food and Drug Administration approval of transcatheter AVR (TAVR). Nevertheless, there is a robust body of real-world data documenting good outcomes with TAVR in this population. In this Expert Perspectives webinar, three noted cardiologists review how the distinct morphologic features of bicuspid valves may impact TAVR outcomes and provide insights on the factors that determine which patients with bicuspid anatomy are candidates for TAVR and which may be better served by a traditional surgical approach.

Duration: 1 hour

CEU Value: 1

Expires: June 9, 2023

CSCT CEU STANDARDS SECTION: 2F

Link:  Individual PAH Treatment to Ensure Optimal Outcomes | myCME  

Description:

Program Description

In this activity, leading experts discuss appropriate diagnostic measures that differentiate pulmonary arterial hypertension (PAH) from other disorders. Additionally, these experts will provide strategies on individualizing treatment for patients with PAH based on the latest practice-altering clinical trial data in the field of PAH.

Duration: 30 minutes

CEU Value: 0.5

Expires: May 10, 2023

CSCT CEU STANDARDS SECTION: 2F

Link:    HCM Around the Globe: Not an Isolated Issue | myCME    

Description:

Program Description

Hypertrophic cardiomyopathy (HCM) is an under-recognized, common, and treatable genetic disease occurring worldwide. HCM is a myocardial disorder most often caused by mutations in one of several sarcomere genes that encode components of the contractile apparatus of the heart. It is characterized by ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. Adding to the burden of disease, HCM can present with a variety of symptoms mimicking other conditions and may go undiagnosed for many years and it is estimated that approximately one in 500 individuals in the United States may have clinically unrecognized, undiagnosed HCM, with an overall prevalence estimated at 750,000.

Please join Dr. Maron and Dr. Torres in this first installment of a CMEO Snack series as they discuss strategies for optimal screening of HCM in an effort to increase recognition and diagnosis of this too often misdiagnosed disease.

Duration: 1 hour

CEU Value: 1 

Expires: December 27, 2022

CSCT CEU STANDARDS SECTION: 2F

Link:  Treatments to Reduce CVD Risk in Patients with Diabetes | myCME 

Description:

Program Description

Patients with type 2 diabetes mellitus are prone to hypertension, dyslipidemia, and coronary artery disease leading to a high risk of myocardial infarction, heart failure, and stroke in these patients. Adequate control of diabetes mellitus is essential to mitigate this risk, and underlying co-morbidities such as hypertension and dyslipidemia must be well controlled to minimize cardiovascular risks in patients with type 2 diabetes. However, there is no set algorithm to achieve this target, and a patient-centered approach, evaluating their specific risk factors, is warranted. Choice of medical therapy should be individualized to obtain the best possible outcome for each patient. Initial treatment rests on educating the patient about glycemic control and appropriate lifestyle changes such as tobacco cessation, increasing exercise, and reducing body weight. However, patients with established cardiovascular disease or those at high risk of this disease warrant special consideration to prevent poor outcomes. This activity describes the evaluation and management of cardiovascular risks in patients with type 2 diabetes mellitus and emphasizes using sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor antagonist (GLP-1RA) drugs in conjunction with insulin to mitigate this risk. It also highlights the role of the interprofessional team in improving care for patients with these conditions.

Duration: 1 hour

CEU Value: 1 (All Components must be completed)

Expires: December 27, 2022

CSCT CEU STANDARDS SECTION: 2F

Link:    Heart Failure With Preserved Ejection Fraction as an Exercise Deficiency Syndrome: JACC Focus Seminar 2/4 | Journal of the American College of Cardiology 

Program Description

Across differing spectrums of cardiac function and cardiac pathologies, there are strong associations between measures of cardiorespiratory fitness and burden of symptoms, quality of life, and prognosis. In this part 2 of a 4-part series, we contend that there is a strong association among physical activity, cardiorespiratory fitness, and cardiac function. We argue that a chronic lack of exercise is a major risk factor for heart failure with preserved ejection fraction in some patients. In support of this hypothesis, increasing physical activity is associated with greater cardiac mass, greater stroke volumes, greater cardiac output and peak oxygen consumption, and fewer clinical events. Conversely, physical inactivity results in cardiac atrophy, reduced output, reduced chamber size, and decreased ability to augment cardiac performance with exercise. Moreover, physical inactivity is a strong predictor of heart failure risk and death. In sum, exercise deficiency should be considered part of the broad heart failure with preserved ejection fraction phenotype.